Astellas CMO successor to follow OV development as next wave
August 05, 2022 - " As Bernhardt Zeiher retires from Astellas’ chief medical officer position, the selection of his successor says a lot about the changes he’s seen at the company over his 12-year tenure.
Looking back on his time, Zeiher told Endpoints News that he believes the successes his group — spanning almost 2,700 people — has had with the current pipeline sets the company up for the next wave of cancer therapies, be it bifunctional antibodies, cell therapies or oncolytic viruses."
https://endpts.com/astellas-taps-seasoned-cmo-amid-shift-to-oncology-doug-manion-steps-into-a-new-arena-following-6-7b-buyout/